CCA
PRVL

Catalyst Capital Advisors’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Catalyst Capital Advisors’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-500
Closed -$7K – 511
2019
Q2 		$7K Buy
+500
New +$7.29K ﹤0.01% 368

Other funds holding PRVL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Catalyst Capital Advisors's PRVL Position: Q3 2019 in Review

Catalyst Capital Advisors sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q3 2019, closing a stake of 500 shares — an estimated $7K sold.

Catalyst Capital Advisors first reported a position in PRVL in Q2 2019 and held it in 1 quarter. The position peaked at $7K in Q2 2019. 42 funds tracked by Wall St. Rank hold PRVL as of Q3 2019.

  • Catalyst Capital Advisors reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 500 Prevail Therapeutics Inc. Common Stock shares in Q3 2019, an estimated $7K.
  • Catalyst Capital Advisors first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's Prevail Therapeutics Inc. Common Stock position peaked at $7K in Q2 2019.
  • 42 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q3 2019.

Based on Catalyst Capital Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.